Two decades of off-label prescribing in children: a literature review

被引:63
|
作者
Balan, Shamala [1 ]
Hassali, Mohamed Azmi Ahmad [1 ]
Mak, Vivienne S. L. [2 ]
机构
[1] Univ Sains Malaysia, Discipline Social & Adm Pharm, Sch Pharmaceut Sci, Gelugor 11800, Penang, Malaysia
[2] Monash Univ, Ctr Med Use & Safety, Fac Pharm & Pharmaceut Sci, Melbourne, Vic, Australia
关键词
Children; Dose; Indication; Off-label; Pediatric; ADVERSE DRUG-REACTIONS; INTENSIVE-CARE-UNIT; 3 PEDIATRIC WARDS; HOSPITALIZED CHILDREN; UNLICENSED DRUGS; MEDICATION USE; EUROPEAN REGULATION; MEDICINES; PRESCRIPTION; INFORMATION;
D O I
10.1007/s12519-018-0186-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundIn the past two decades, many legislative and regulatory initiatives were taken globally to improve drug use in children. However, children are still found to be prescribed with off-label drugs. This study was conducted to provide an overview of the worldwide trend in off-label prescribing in children from the year 1996 to 2016.Data sourcesThe articles published in PubMed, MEDLINE and Google Scholar were searched using text words: off-label, unlicensed, paediatric and children. Additional articles were identified by reviewing the bibliography of the retrieved articles. Full-text articles published in English which reported on the prevalence of off-label prescribing in children between January 1996 and December 2016 were included.ResultsA total of 101 studies met the inclusion criteria. Off-label prescribing definition included four main categories: age, indication, dose and route of administration. The three most common reference sources used in the studies were summary of product characteristics, national formularies and package inserts. Overall, the off-label prescribing rates in children ranged from 1.2 to 99.7%. The most common category of off-label prescribing in children was dose and age.ConclusionsThis review highlighted that off-label prescribing in children was found to be highly prevalent throughout the past two decades, persistently in the neonatal intensive care units. This suggests that besides legislative and regulatory initiatives, behavioural, knowledge aspects and efforts to integrate evidence into practice related to off-label prescribing also need to be evaluated and consolidated as part of the concerted efforts to narrow the gaps in prescribing for children.
引用
收藏
页码:528 / 540
页数:13
相关论文
共 50 条
  • [31] In Defense of Off-label Prescribing Reply
    Eguale, Tewodros
    Verma, Aman
    Tamblyn, Robyn
    JAMA INTERNAL MEDICINE, 2016, 176 (06) : 861 - 862
  • [32] Paediatric Off-Label Prescribing in the USA
    不详
    PHARMACEUTICAL MEDICINE, 2019, 33 (06) : 533 - 534
  • [34] Assessment off-label prescribing in dermatology
    Picard, D
    Carvalho, P
    Bonnavia, C
    Louin, L
    Josset, V
    Lauret, P
    Joly, P
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2003, 130 (05): : 507 - 510
  • [35] Off-label Prescribing in Pediatric Outpatients
    Dackiewicz, Nora
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2015, 113 (04): : 383 - 384
  • [36] Off-label prescribing: a matter of trust
    Allison, Susan J.
    NATURE REVIEWS NEPHROLOGY, 2010, 6 (08) : 441 - 441
  • [37] Off-Label Prescribing in Older Patients
    Jackson, Stephen H. D.
    Jansen, Paul A. F.
    Mangoni, Arduino A.
    DRUGS & AGING, 2012, 29 (06) : 427 - 434
  • [38] Tamiflu® and abuse of off-label prescribing
    Wilks, Colin
    AUSTRALIAN VETERINARY JOURNAL, 2011, 89 (11)
  • [40] The Many Sides of Off-Label Prescribing
    Epstein, R. S.
    Huang, S-M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (05) : 755 - 758